As research continues to explore B cell autoimmunity, B cell-mediated therapies likely will pursue increasingly specific targets, says Arthur Kavanaugh, M.D.
The Weekly Roundup: September 23-27
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
LEO Pharma Presents Extensive Data at EADV
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits